It was late April when the CDC added impaired taste and/or smell to its list of COVID-19 symptoms. Thanks to AI and natural language processing (NLP), researchers at the Medical University of South Carolina had beaten the federal agency to the punch.
AI enthusiasts have varying aims and incentives for pushing the technology into healthcare, but many parrot a common set of justifications. Do any of these sound familiar?
Researchers have demonstrated a way to visually explore small-molecule inhibitors that, according to algorithmic suggestions, show potential for targeting COVID-19’s main proteins.
After seeing telehealth visits skyrocket 3,700% in April over March—most of them COVID-related—UPMC is touting its use of AI to help patients retain and apply doctors’ guidance offered during virtual visits.
Understood as a virtual army in the war against COVID-19, AI has vast stockpiles of potential weaponry with which to wage many a battle. That’s the good news.
COVID-19 isn’t only keeping patients home when they should be seeing their doctors. It’s also keeping clinical investigators from moving ahead with their research.
Notching its fifth go-ahead from the FDA, an Israel-based AI startup has received the agency’s 510(k) clearance to market software that automatically identifies signs of compression fractures in the spine.
